🧠Brain+ is on a mission to make effective #dementia treatments availability to everyone as #DigitalTherapeutics. We are founded on the fact that ‘our brains can change all throughout our life’ . Our brain has the quality of #neuroplasticity, the ability to restructure 🛠 ➡ 🧠

Happy to announce that we’ve been named one of Hello Tomorrow’s Deep Tech Pioneers! Selected from thousands of applications, we will be attending the Hello Tomorrow Global Summit, March 9-10th 2023. More information and tickets here 👉hello-tomorrow.org/global-summit/…

I'm happy to announce that Brain+ has successfully completed the implementation of an ISO 13485-compliant Quality Management System (QMS). 💎This is testament to our commitment to developing both safe and highly effective digital therapeutics. Brain+

Ps. Join our investor webinar TODAY @ 16:30 to 17:00 CET to update on the company’s commercial activities. Sign up : tinyurl.com/3jnnn8uf

First sale!!! 🚀 ...and Happy New Year!!! ⏱ ...I'm happy to say that we on the December 31. we could announce the first sale of our dementia product, the Brain+ CST Therapist Companion, to the Danish municipality of Herning. #healthyageing #dementia #dtx #Alzheimers #CST

Great news for the Alzheimer’s space! 🎉 ….The FDA approves Alzheimer’s drug, Lecanemab, that slows cognitive decline for the US market. ✳ It is great news for Brain+, as our Digital Therapeutics products which also target the slowing down and prevention of cognitive decline!

Vi møder Dansk Aktionærforening til en nytårsstatus! 🎊 …og taler om seneste nyt i Brain+ inklusiv salget til Herning Kommune 💰, gode nyheder fra et studie på Nottingham Universitet på vores kognitivt træningsteknologi , og vi kigger fremad i 2023 lnkd.in/eWwwt_gS

Aktier i Fokus, Anders Egsvang Rasmussen, interviewede mig i en lille time om Brain+, lyt med her og få et mere dybdegående indblik i Brain+ 👁 Link til Spotify: lnkd.in/eB-E3Vw7 Link til Apple Podcast: lnkd.in/emmukZRa

McKinsey & Company report on #DigitalTherapeutics “Incumbents that move quickly still have an opportunity to gain a first-mover advantage in the growing digital therapeutics sector, where promising start-ups can receive multibillion-dollar valuations.” lnkd.in/e6hT42Ak

Important opportunity for Brain+ to present its innovative digital solutions for better care and treatment of Alzheimer’s and other types of dementia to key Japanese industry and academic stakeholders. Read more: brain-plus.com/matsumae-busin… #alzheimers #dementia #DTx

🇯🇵 Konnichiwa! ... Today the mayor of the Danish municipality Vejle, Jens Ejner Christensen, welcomed the Japanese ambassador, H.E. Uyama Hideki, and a Japanese delegation to the Matsume Business Cup, aiming to present the most promising Danish welfare and health tech solutions!

Congrats to our talented CFO for being selected among the Top-100 Danish business talent. Brain+ berlingske.dk/talent-100/ber…

Learn more about the current Brain+ unit rights issue: Topics discussed: - Turbulent market conditions - Existing shareholders - What you get in the rights issue - Use of funds - The business case of Brain+ vimeo.com/824981924

Apps are changing the world of medicine, offering unprecedented ways to handle our health. Regulatory issues can put connected health innovation at risk. Learn more from Kim Baden-Kristensen, co-founder & CEO of member company Brain+. actonline.org/2020/11/08/mem…

🚀 Takeoff for Dtx Europe London 2023 🚀 @British Medical Association House Dtx Experts and veterans debate the leanings from DIGA in Germany... brain+ on stage later to present #dtx HTN Health Tech News Barry Shrier

Great insights from Kim Baden-Kristensen of Brain+ delving into evidence generation strategies for #digitaltherapeutics at #DTxEurope

1/x Nyttjandeperioden för Brain+ T02 pågår mellan 2–16 oktober 2023. Nedan finner ni en VD-intervju med Kim Baden-Kristensen samt en casetråd för den som vill veta mer om bolaget👇 $BRAINP

2/x VD-intervju: x.com/kalqyl/status/…

3/x Casetråd: x.com/kalqyl/status/…

Det totala teckningsåtagandet i Brain+ uppgår nu till 35% av de utestående optionerna. Sex av de bolagets största aktieägare har åtagit sig att teckna TO2 för 1,6 MDKK. Utöver detta har CEO, CFO och delar av styrelsen åtagit sig att teckna för 0,4 MDKK. Sista dag för handel av